Selank vs Semax vs Dihexa: Cognitive Peptide Showdown

When it comes to nootropic peptide research, Selank, Semax, and Dihexa represent three of the most closely studied compounds in the cognitive signaling space. Each peptide operates through distinct neurochemical pathways, and understanding those differences is central to designing meaningful preclinical research. While all three have been explored in the context of cognitive function, their mechanisms, molecular targets, and research profiles diverge in ways that matter significantly to laboratory investigators.

This comparison article breaks down each compound individually before placing them side by side — covering receptor interactions, study findings, research applications, and how scientists approach choosing between them depending on their experimental focus.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. These compounds are intended for use in controlled research environments only and are not approved for human consumption or therapeutic application.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

Selank — 10MG

Selank - 10MG — Research-Grade Reference Material Selank - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$45.00 ($33.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is the main difference between Selank, Semax, and Dihexa?

Selank is a synthetic heptapeptide primarily studied for its anxiolytic and immunomodulatory properties via GABAergic and serotonergic pathways. Semax is an ACTH-derived peptide investigated for its BDNF-upregulating and neuroprotective properties. Dihexa is a small, highly potent peptide studied for its role in HGF/MET receptor activation and synaptogenesis. All three are explored in cognitive research but target different molecular mechanisms.

Is Selank or Semax better for anxiety-focused research models?

Selank has been more specifically studied in anxiety-related models due to its interaction with GABAergic signaling and enkephalin degradation. Semax has also shown anxiolytic properties in some preclinical models, but its primary research focus tends toward neuroprotection, BDNF expression, and cognitive enhancement rather than anxiety modulation specifically.

How potent is Dihexa compared to other cognitive peptides?

Research suggests Dihexa may be significantly more potent than BDNF itself in certain synaptogenesis models, with some studies noting activity at very low concentrations. It is considered a highly potent compound in preclinical cognitive research settings, particularly in models involving HGF/MET signaling and dendritic spine formation.

Can Selank and Semax be used together in research?

Some researchers investigate Selank and Semax together, given their complementary mechanisms — Selank’s focus on anxiety and immune modulation alongside Semax’s emphasis on BDNF and neuroprotection. A combined nasal spray formulation exists for research procurement purposes, though study designs using both compounds should account for their distinct receptor interactions.

What research models are Dihexa most commonly studied in?

Dihexa has been studied primarily in neurodegeneration and cognitive impairment models, including those involving Alzheimer’s-related pathology. Its role in promoting synaptogenesis and activating the hepatocyte growth factor (HGF) system makes it a candidate for investigations into memory formation and neural circuit plasticity.

What delivery methods are used in research for these peptides?

All three peptides have been investigated using intranasal and subcutaneous delivery routes in research settings. Intranasal administration is of particular interest given the olfactory pathway’s proximity to the central nervous system, which may support CNS bioavailability in preclinical models.

Are these peptides studied for long-term cognitive effects?

Yes. Research on Semax and Dihexa in particular has included longer-duration models examining sustained changes in BDNF levels, synaptic density, and cognitive task performance in animal subjects. Selank’s longer-term studies have focused more on anxiety-like behavior and immune marker changes over time.

Selank: Anxiolytic Peptide With Broad Neurochemical Reach

Selank is a synthetic heptapeptide developed from the endogenous tetrapeptide tuftsin. Structurally defined as Thr-Lys-Pro-Arg-Pro-Gly-Pro, it was developed by the Institute of Molecular Genetics in Russia and has been investigated extensively in the context of anxiety, cognitive performance, and immune function. The Selank peptide research guide covers the full spectrum of its documented mechanisms, but the highlights are worth examining here in direct comparison to its counterparts.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

Selank — 10MG

$45.00 ($33.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

At the mechanistic level, Selank is believed to influence the metabolism of enkephalins — endogenous opioid peptides involved in mood regulation — by inhibiting their enzymatic breakdown. This interaction may contribute to its documented anxiolytic effects in preclinical models. Additionally, Selank has been shown to modulate GABA-A receptor activity and affect the expression of serotonergic and dopaminergic signaling components, giving it a broad-spectrum neurochemical profile.

Key Research Findings for Selank

Preclinical models have reported reduced anxiety-like behavior in rodent subjects following Selank administration
Studies have investigated upregulation of BDNF and other neurotrophic markers, though to a lesser degree than Semax
Immunomodulatory properties have been explored, particularly related to interleukin expression
Research suggests potential effects on memory consolidation and learning in maze-based animal models
Well-documented enkephalin degradation inhibition distinguishes its mechanism from the other two compounds

Selank 10MG Nasal Spray for research →

Semax: BDNF Upregulation and Neuroprotective Signaling

Semax is a heptapeptide analog of ACTH(4-10), the adrenocorticotropic hormone fragment. It was developed in Russia and has accumulated a notable preclinical and some clinical research literature — particularly around its ability to upregulate brain-derived neurotrophic factor (BDNF), a key protein involved in neuronal survival, plasticity, and learning. As explored in the article on what Semax is and how it functions, the peptide’s ACTH-derived backbone gives it a unique relationship with melanocortin receptors.

Semax activates melanocortin receptor subtypes (MC1R, MC3R, and MC4R) and is thought to exert its cognitive and neuroprotective effects partly through these interactions and partly through downstream upregulation of neurotrophic signaling cascades. In animal models of ischemia, cognitive impairment, and neurological stress, Semax has consistently shown measurable effects on BDNF expression and related markers of neural resilience.

Key Research Findings for Semax

Consistent BDNF upregulation observed across multiple preclinical models, including ischemic injury studies
Investigations into neuroprotective effects following neurological stress events in animal subjects
Cognitive task performance improvements noted in rodent models of impaired learning
Melanocortin receptor activation may contribute to attentional and motivational signaling
Research has explored possible applications in neurodegenerative disease models

Researchers interested in combined administration of both Selank and Semax may find the full comparison of Selank vs Semax useful for designing targeted study protocols where complementary mechanisms are relevant.

Semax 10MG Nasal Spray for research →

Dihexa: HGF Signaling and Synaptogenesis Research

Dihexa (also referred to as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) occupies a distinct category among cognitive research peptides. Unlike Selank and Semax, which interact primarily with neurotransmitter systems and neurotrophic pathways, Dihexa targets the hepatocyte growth factor (HGF) / MET receptor system — a signaling axis not traditionally associated with cognitive research until relatively recently. A detailed breakdown of this mechanism is available in the Dihexa peptide research overview.

What makes Dihexa particularly compelling in the cognitive research space is its potency. Research originating from Washington State University has suggested that Dihexa may be several orders of magnitude more potent than BDNF itself in promoting synaptogenesis — a finding that has generated significant scientific interest. The compound appears to work by potentiating HGF binding to MET receptors, which in turn drives downstream signaling cascades associated with dendritic spine formation and synaptic density increases.

Key Research Findings for Dihexa

HGF/MET receptor potentiation studied in models of Alzheimer’s disease and age-related cognitive decline
Synaptogenesis promotion at remarkably low concentrations in animal tissue studies
Improvements in spatial memory tasks reported in rodent models of induced cognitive impairment
Research on dendritic spine density suggests structural neural changes with Dihexa exposure
High lipophilicity allows for brain penetration, which is relevant for CNS-targeted research designs

The broader landscape of cognitive peptide research — including comparisons between Dihexa and Semax — is covered in the Dihexa vs Semax article, which provides additional context on experimental design choices.

Dihexa 10MG for research →

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

Side-by-Side Comparison Table

Feature	Selank	Semax	Dihexa
Peptide origin	Tuftsin analog (synthetic)	ACTH(4-10) analog	Angiotensin IV analog
Primary mechanism	GABAergic, enkephalin inhibition	Melanocortin receptor activation	HGF/MET receptor potentiation
BDNF involvement	Moderate, indirect	Strong, direct upregulation	Independent; synaptogenesis-focused
Anxiety model research	Extensively studied	Some evidence, secondary focus	Not a primary research focus
Neuroprotection research	Moderate evidence	Strong evidence (ischemia models)	Neurodegeneration model focus
Potency profile	Moderate	Moderate-high	Very high (sub-nanomolar range)
Immunomodulation	Yes — documented	Limited evidence	Not a primary focus
Research delivery	Intranasal, subcutaneous	Intranasal, subcutaneous	Oral, subcutaneous studied

Choosing a Focus: Research Design Decision Guide

Choose Selank if…

Your research model focuses on anxiety-like behavior or stress-related neurochemistry
You are investigating GABAergic or enkephalin-mediated signaling pathways
Your study design includes immune marker measurement (e.g., interleukin expression)
You want a well-characterized, moderate-potency compound with a broad neurochemical footprint

Choose Semax if…

Your primary research endpoint involves BDNF quantification or neurotrophic signaling
You are working in stroke, ischemia, or neurological injury models
Your study involves melanocortin receptor pathway analysis
You are exploring sustained neuroprotective effects over longer experimental timelines

Choose Dihexa if…

Your research is centered on synaptogenesis, dendritic density, or structural neural changes
You are working in Alzheimer’s disease or age-related cognitive impairment models
Your experimental design requires a highly potent compound at low concentrations
You are investigating HGF/MET receptor biology in a CNS context

For researchers who want to explore both Selank and Semax within the same study framework, the Selank + Semax 20MG Nasal Spray combination → is available for laboratory procurement.

Where These Fit in Your Research Library

These three peptides are among the most studied entries in the broader nootropic peptides research guide, which provides additional context on how cognitive signaling compounds are categorized and studied. Researchers building out a full cognitive peptide library may also wish to explore complementary compounds.

Final Takeaway: Three Compounds, Three Research Angles

Selank, Semax, and Dihexa each bring a distinct mechanistic angle to cognitive peptide research. Selank is the compound of choice for anxiety-model research and GABAergic pathway investigation. Semax stands out for its robust BDNF-upregulating properties and its relevance to neuroprotection and ischemia models. Dihexa occupies a unique niche as an exceptionally potent synaptogenesis promoter with HGF/MET-focused mechanisms — making it particularly relevant for researchers studying structural neural changes and neurodegeneration pathology.

Rather than competing, these three peptides effectively map out complementary territories in cognitive neuroscience research. Understanding their differences allows investigators to select the most appropriate compound — or combination of compounds — for their specific experimental hypotheses and biological endpoints. Whether the focus is on stress signaling, neurotrophic factor expression, or synaptic architecture, each of these peptides offers a well-defined lens through which to study the neurobiology of cognition.

Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.